On this episode of Ethics Talk, Zahra H. Khan, Yoshiko Iwai, and Dr Sayantani DasGupta outline how “abolition medicine” can motivate critical responses to medicine’s expressions of hyper-punitive, deeply racialized exercises of state authority.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.